GliclazideThird Party Manufacturing in India

Gliclazide works by stimulating insulin secretion from the beta cells of the pancreas, an effect that helps lower blood glucose levels in patients with type 2 diabetes mellitus. It belongs to the sulfonylurea class of insulin secretagogues.

As a second-generation sulfonylurea, gliclazide binds to the sulfonylurea receptor (SUR1) on the surface of pancreatic beta cells. This binding leads to the closure of ATP-sensitive potassium channels, which causes depolarization of the beta cell membrane. The depolarization triggers the opening of voltage-dependent calcium channels, allowing calcium ions to flow into the cell. The resulting increase in intracellular calcium concentration stimulates the exocytosis of insulin granules, releasing insulin into the bloodstream.

A key differentiating feature of gliclazide compared to other sulfonylureas is its additional haemovascular properties. Gliclazide decreases microthrombosis through two distinct mechanisms — partial inhibition of platelet aggregation and adhesion, with a reduction in markers of platelet activation such as beta thromboglobulin and thromboxane B2, and an action on the vascular endothelium that enhances fibrinolytic activity by increasing tissue plasminogen activator activity. These vascular effects are particularly relevant in diabetic patients who have an elevated risk of microvascular complications.

In type 2 diabetics, gliclazide restores the first peak of insulin secretion in response to glucose and augments the second phase of insulin secretion, resulting in improved postprandial glucose control. The increase in insulin and C-peptide secretion persists even after two years of continued treatment, indicating sustained efficacy without rapid beta-cell exhaustion.

Therapeutic Uses

Gliclazide is prescribed for the treatment of:

• Type 2 Diabetes Mellitus: Gliclazide is indicated as a first-line or second-line oral antidiabetic agent for adults with type 2 diabetes when dietary measures, physical exercise, and weight loss alone are insufficient to control blood glucose levels.
• Combination Therapy: It is widely used in combination with other antidiabetic agents such as metformin, pioglitazone, or insulin when monotherapy does not achieve adequate glycemic control.
• Prevention of Microvascular Complications: Through its haemovascular properties, gliclazide may help reduce the risk of diabetic microvascular complications including retinopathy, nephropathy, and neuropathy.

Why Manufacturers Choose Gliclazide

Gliclazide is one of the most widely prescribed sulfonylureas globally, particularly in India and developing markets, due to its favorable safety profile and additional vascular benefits compared to older sulfonylureas like glibenclamide. It is a high-volume molecule in the Indian pharmaceutical manufacturing market, with consistent demand from both domestic PCD franchise networks and export-oriented companies serving Africa, Asia, and the Middle East.

The availability of multiple dosage forms — immediate release tablets and modified release formulations — allows manufacturers to offer a complete diabetes management portfolio under one brand. Gliclazide's stable regulatory status across pharmacopoeias (IP, USP, BP) makes it an ideal candidate for WHO-GMP certified facilities seeking to supply regulated and semi-regulated markets.

This makes Gliclazide one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.